Early diagnosis and staging

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 3331, 1999, Pages 15-18

  Lilja, H ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Benign prostate hyperplasia; Prostate cancer; Prostate specific antigen; Transrectal ultrasound; 1 antichymotrypsin

Indexed keywords

EID: 27844499483     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500271     Document Type: Article

References (39)

1. Stephenson RA. Prostate cancer trends in the PSA era: data from the SEER program. AUA News 1997; 15-22.
2. Wingo PA, Landis S, Ries L. An adjustment to the 1997 estimate for new prostate cancer cases. Cancer 1997; 80: 1810-1813.
3. Hoeksema MJ, Law C. Cancer mortality rates fall: A turning point for the nation. J Natl Cancer Inst 1996; 88: 1706-1707.
4. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954.
5. Catalona WJ et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-1290.
6. Benson MC et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-816.
7. Carter HB et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-2220.
8. Stamey TA et al. A neural network (Prostasure™) with high sensitivity and specificity for diagnosing prostate cancer in men with a PSA < 4.0 ng/mL. J Urol 1997; 157 (Suppl): 364.
9. Oesterling JE, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860-864.
10. Moul JW et al. Prostate-specific antigen levels at the time prostate cancer diagnosis are higher in African-American Men. JAMA 1995; 274: 1277-1281.
11. Morgan TO et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304-310.
12. Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-763.
13. Lilja H et al. Prostate-specific antigen in human serum occurs predominantly in complex with a1-antichymotrypsin. Clin Chem 1991; 37: 1618-1625.
14. Stenman UH et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222.
15. Christensson A et al. Serum prostate-specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-105.
16. Mitrunen K et al. Dual-label one-step immunoassay for simultaneous measurement of free and total PSA concentrations and ratios in serum. Clin Chem 1995; 41: 1115-1120.
17. Björk T et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996; 48: 882-888.
18. Lodding P et al. Characteristics of screening detected prostate cancer in men 50 to 65 years old with 3 to 4 ng/mL prostate-specific antigen. J Urol 1998; 159: 899-903.
19. Lövgren J et al. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Comm 1997; 238: 549-555.
20. Piironen T et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996; 42: 1034-1041.
21. Shinohara K, Scardino PT, Carter SC, Wheeler TM. Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am 1989; 16: 675.
22. Lee F et al. Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate 1985; 7: 117.
23. Loch T et al. Computer assisted image analysis of prostate ultrasound in the diagnosis of carcinoma of the prostate. J Urol 1989; 141: 348.
24. Loch T et al. Computer-aided image-analysis in transrectal ultrasound of the prostate. World J Urol 1990; 8: 150.
25. Loch T et al. Neural network analysis of subvisual transrectal ultrasound data: improved prostate cancer detection. J Urol 1997; 157 (Suppl): 364.
26. Stamey TA et al. Localized prostate cancer: Relationship of tumor volume to clinical significance for the treatment of prostate cancer. Cancer 1993; 71: 993.
27. Hanley JA, McNeil, BJ. The meaning and use of the area under the receiver operator characteristic (ROC) curve. Radiology 1982; 143: 29.
28. Benson et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817.
29. Brawer MK et al. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993; 150: 369.
30. Weber JP et al. The influence of reversible androgen deprivation on serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141: 987.
31. Brawer MK. How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA Cancer J Clin 1995; 45: 148.
32. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45: 2.
33. Porter JR, Hayward R, Brawer MK. The significance of short-term PSA change in men undergoing ultrasound-guided prostate biopsy. J Urol 1994; 151 (Suppl): 239A.
34. Carter HB et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45: 591.
35. Lanz KJ et al. Biologic variation in serum PSA level. J Urol 1996; 155: (Suppl) 696A.
36. Partin AW, Oesterling, JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358.
37. Oesterling JE et al. Influence of patient age on the serum PSA concentration, an important clinical observation. Urol Clin North Am 1993; 20: 671.
38. Catalona WJ et al. Evaluation of percentage of free serum pros-tate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214.
39. Ellis WJ, Brawer MK. Repeat needle biopsy: who needs it? J Urol 1995; 153: 1496.